U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H7NO3
Molecular Weight 153.1357
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MESALAMINE

SMILES

c1cc(c(cc1N)C(=O)O)O

InChI

InChIKey=KBOPZPXVLCULAV-UHFFFAOYSA-N
InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)

HIDE SMILES / InChI

Molecular Formula C7H7NO3
Molecular Weight 153.1357
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/mtm/mesalamine.html

Mesalamine, also known as Mesalazine or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalicylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects. As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism. Although the mechanism of action of mesalazine is not fully understood, it appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon. Mesalazine is used for the treatment of active ulcerative proctitis.

CNS Activity

Curator's Comment:: Mesalazine and acetyl mesalazine do not cross the blood brain barrier.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PENTASA

Approved Use

PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.

Launch Date

7.3690559E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
150 ng/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1595 ng/mL
2.4 g single, oral
dose: 2.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2154 ng/mL
4.8 g single, oral
dose: 4.8 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
857 ng/mL
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
909 ng × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
21084 ng × h/mL
2.4 g single, oral
dose: 2.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
44775 ng × h/mL
4.8 g single, oral
dose: 4.8 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
9578 ng × h/mL
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
25 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
7.05 h
2.4 g single, oral
dose: 2.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
7.25 h
4.8 g single, oral
dose: 4.8 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
8.56 h
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
57%
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
14.5 g single, oral|rectal (complex)
Overdose
Dose: 14.5 g
Route: oral|rectal
Route: single
Dose: 14.5 g
Sources:
unhealthy, 20 - years
n = 1
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: 20 - years
Sex: M
Population Size: 1
Sources:
Disc. AE: Intoxication...
AEs leading to
discontinuation/dose reduction:
Intoxication (1 patient)
Sources:
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, 28 - 41 years
n = 10
Health Status: unhealthy
Condition: Inflammatory bowel disease, breastfeeding mothers
Age Group: 28 - 41 years
Sex: F
Population Size: 10
Sources:
15.7 mg/kg 1 times / day steady, oral (mother), breasteeding (infant) (mean)
Dose: 15.7 mg/kg, 1 times / day
Route: oral (mother), breasteeding (infant)
Route: steady
Dose: 15.7 mg/kg, 1 times / day
Sources:
healthy, 35–251 days
n = 10
Health Status: healthy
Age Group: 35–251 days
Sex: M+F
Population Size: 10
Sources:
3.2 g 1 times / day steady, oral
Recommended
Dose: 3.2 g, 1 times / day
Route: oral
Route: steady
Dose: 3.2 g, 1 times / day
Sources:
unhealthy, 42 years
n = 1
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: 42 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hypersensitivity...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity (1 patient)
Sources:
1.6 g 1 times / day steady, oral (median)
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Disc. AE: Anxiety, Headache...
AEs leading to
discontinuation/dose reduction:
Anxiety (1 patient)
Headache (1 patient)
Pruritus (1 patient)
Libido decreased (1 patient)
Rheumatoid arthritis (1 patient)
Asthenia (1 patient)
Sources:
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Disc. AE: Diarrhea, Colitis...
AEs leading to
discontinuation/dose reduction:
Diarrhea (1 patient)
Colitis (1 patient)
Dizziness (1 patient)
Nausea (1 patient)
Joint pain (1 patient)
Headache (2 patients)
Rash (1 patient)
Lethargy (1 patient)
Constipation (1 patient)
Dry mouth (1 patient)
Malaise (1 patient)
Back discomfort (1 patient)
Disorientation (1 patient)
Indigestion (1 patient)
Nausea (1 patient)
Generalised aching (1 patient)
Vomiting (1 patient)
Muscle cramps (1 patient)
Nasal congestion (1 patient)
Eustachian tube obstruction (1 patient)
Fever (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Intoxication 1 patient
Disc. AE
14.5 g single, oral|rectal (complex)
Overdose
Dose: 14.5 g
Route: oral|rectal
Route: single
Dose: 14.5 g
Sources:
unhealthy, 20 - years
n = 1
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: 20 - years
Sex: M
Population Size: 1
Sources:
Hypersensitivity 1 patient
Disc. AE
3.2 g 1 times / day steady, oral
Recommended
Dose: 3.2 g, 1 times / day
Route: oral
Route: steady
Dose: 3.2 g, 1 times / day
Sources:
unhealthy, 42 years
n = 1
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: 42 years
Sex: M
Population Size: 1
Sources:
Anxiety 1 patient
Disc. AE
1.6 g 1 times / day steady, oral (median)
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Asthenia 1 patient
Disc. AE
1.6 g 1 times / day steady, oral (median)
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Headache 1 patient
Disc. AE
1.6 g 1 times / day steady, oral (median)
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Libido decreased 1 patient
Disc. AE
1.6 g 1 times / day steady, oral (median)
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Pruritus 1 patient
Disc. AE
1.6 g 1 times / day steady, oral (median)
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Rheumatoid arthritis 1 patient
Disc. AE
1.6 g 1 times / day steady, oral (median)
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Back discomfort 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Colitis 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Constipation 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Diarrhea 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Disorientation 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Dizziness 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Dry mouth 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Eustachian tube obstruction 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Fever 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Generalised aching 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Indigestion 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Joint pain 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Lethargy 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Malaise 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Muscle cramps 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Nasal congestion 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Nausea 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Nausea 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Rash 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Vomiting 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Headache 2 patients
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
n = 155
Health Status: unhealthy
Condition: ulcerative colitis
Age Group: adult
Sex: unknown
Population Size: 155
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
Interstitial nephritis in children with Crohn's disease.
2000 Apr
Mesalamine-induced chest pain: a case report.
2000 May
Pyelonephritis caused by mesalazine.
2000 Oct
Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis.
2001
TNF-alpha induced endothelial MAdCAM-1 expression is regulated by exogenous, not endogenous nitric oxide.
2001
Hydroxyl radical adduct of 5-aminosalicylic acid: a potential marker of ozone-induced oxidative stress.
2001
[The new experimental ulcerative colitis model in rats induced by subserosal injection of acetic acid].
2001 Aug
Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.
2001 Aug
[Metastatic Crohn's disease in childhood].
2001 Aug
Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy.
2001 Aug
Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.
2001 Aug 30
Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats.
2001 Feb
Infliximab for the treatment of orofacial Crohn's disease.
2001 Feb
Look out for toxic effects of mesalamines!
2001 Feb
[Hypersensitivity to mesalazine after severe allergic reaction to sulfasalazine].
2001 Jan
[Guidelines of DGVS. Remission. German Society of Digestive and Metabolic Diseases].
2001 Jan
[Guidelines of the DGVS. Acute process. German Society of Digestive and Metabolic Diseases].
2001 Jan
[Therapy of active Crohn disease with Boswellia serrata extract H 15].
2001 Jan
Can postoperative relapse of Crohn's disease be prevented?
2001 Jan
Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
2001 Jan
Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases?
2001 Jan-Feb
On using the standard gamble to determine utilities for uncertain health states.
2001 Jan-Feb
Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis.
2001 Jul
Mesalamine-induced unilateral eosinophilic pneumonia.
2001 Jul
Oral balsalazide (Colazal) for ulcerative colitis.
2001 Jul 23
Ulcerative colitis associated with interferon treatment for chronic hepatitis C.
2001 Jun
[A case of successful mesalazine enema for rectal cavitating ulcer of Crohn's disease].
2001 Jun
Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.
2001 Jun
Probiotics (Br J Surg 2001; 88: 161-2).
2001 Jun
5-Aminosalicylates in inflammatory bowel disease: choosing the right dose.
2001 Jun-Jul
Lymph folliculitis in ulcerative colitis.
2001 Mar
Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report.
2001 Mar
Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance.
2001 Mar
Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use.
2001 Mar
From the Food and Drug Administration.
2001 Mar 7
What can nephrologists learn from epidemiology?
2001 Mar-Apr
Salvage external beam radiotherapy for clinical failure after cryosurgery for prostate cancer.
2001 Nov 1
Recent advances in the treatment of the seronegative spondyloarthropathies.
2001 Oct
Review article: balsalazide therapy in ulcerative colitis.
2001 Oct
Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study.
2001 Oct
Mesalamine induces manganese superoxide dismutase in rat intestinal epithelial cell lines and in vivo.
2001 Oct
[Collagenous colitis. A study of 11 cases].
2001 Sep
Headache during mesalamine therapy: a case report of mesalamine-induced pseudotumor cerebri.
2001 Sep
Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis.
2001 Sep
The hair of the dog.
2001 Sep
[Generalized pustulous psoriasis: A novel extraintestinal manifestation of Crohn's disease?].
2001 Sep
Review article: current therapeutic options for radiation proctopathy.
2001 Sep
NO-mesalamine protects colonic epithelial cells against apoptotic damage induced by proinflammatory cytokines.
2001 Sep
[Conservative therapy of severe ulcerative colitis. More effective than internists believe!].
2001 Sep 13
5-Aminosalicylate stimulates phospholipase D activity in macrophages.
2001 Sep 28
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: can also be used rectally
Usual Adult Dose for Ulcerative Colitis - Active ORAL: 250 and 500 mg capsules: 1 g orally 4 times a day Duration of therapy: Up to 8 weeks 400 mg tablets: 800 mg orally 3 times a day Duration of therapy: 6 weeks 400 mg delayed release capsules: 800 mg orally 3 times a day Duration of therapy: 6 weeks 800 mg delayed release tablets: 1600 mg orally 3 times a day Duration of therapy: 6 weeks 1200 mg tablets: 2.4 to 4.8 g orally once a day with food
Route of Administration: Oral
Treatment of both HT-29 wild-type, dominant-negative PPARg and empty vector cells HT-29 cells with Mesalamine (30 mM) for 48 h increased the activity of PPARg
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:55:08 UTC 2021
Edited
by admin
on Fri Jun 25 20:55:08 UTC 2021
Record UNII
4Q81I59GXC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MESALAMINE
HSDB   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
MESALAMINE [VANDF]
Common Name English
MESALAMINE [HSDB]
Common Name English
MESALAZINE [EP MONOGRAPH]
Common Name English
MESALAZINE [INN]
Common Name English
MESALAMINE [USP MONOGRAPH]
Common Name English
FISALAMINE
Common Name English
ASACOL
Brand Name English
MESALAZINE [JAN]
Common Name English
ROWASA
Brand Name English
MESALAMINE [MI]
Common Name English
MESALAZINE [EP]
Common Name English
5-AMINOSALICYLIC ACID
Systematic Name English
APRISO
Brand Name English
NSC-38877
Code English
5-AMINO-2-HYDROXYBENZOIC ACID
Systematic Name English
BENZOIC ACID, 5-AMINO-2-HYDROXY-
Common Name English
PENTASA
Brand Name English
MESALAZINE [WHO-DD]
Common Name English
MESALAZINE [MART.]
Common Name English
SFROWASA
Brand Name English
MESALAMINE [USAN]
Common Name English
LIALDA
Brand Name English
MAX-002
Code English
MESALAZINE
EP   INN   JAN   MART.   WHO-DD  
INN  
Official Name English
MESALAMINE [ORANGE BOOK]
Common Name English
MESALAMINE [USP-RS]
Common Name English
CANASA
Brand Name English
IIALDA
Brand Name English
M-AMINOSALICYLIC ACID
Systematic Name English
Classification Tree Code System Code
WHO-VATC QA07EC02
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
FDA ORPHAN DRUG 253607
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
NDF-RT N0000005760
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
LIVERTOX 605
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
NDF-RT N0000005760
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
FDA ORPHAN DRUG 275909
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
FDA ORPHAN DRUG 298109
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
NDF-RT N0000005760
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
NDF-RT N0000005760
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
NDF-RT N0000175781
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
NCI_THESAURUS C257
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
WHO-ATC A07EC02
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C29249
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
LACTMED
Mesalamine
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
MESH
D019804
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
CAS
89-57-6
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
ECHA (EC/EINECS)
201-919-1
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
DRUG CENTRAL
1710
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
FDA UNII
4Q81I59GXC
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
HSDB
7512
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
PUBCHEM
4075
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
EVMPD
SUB08782MIG
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
EPA CompTox
89-57-6
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
IUPHAR
2700
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
RXCUI
52582
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
MESALAZINE
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
DRUG BANK
DB00244
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
ChEMBL
CHEMBL704
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
INN
5444
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
USP_CATALOG
1392705
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M7244
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY Merck Index
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE ACTIVE
Inhibite the Hb-catalyzed peroxidative reaction
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 2.0
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 1.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 4.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC